Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Administrative · Pharmacy · NJ · Neurology, Pediatrics, Pharmacy +1 moreLow impact

MA08.086d, Nusinersen (Spinraza®)

Effective date
Not stated in the notice
Identified
Jun 19, 2026

Summary

Independence Blue Cross reissued Medicare Advantage policy MA08.086d for Nusinersen (Spinraza®) on March 4, 2026, as part of the annual review process. The policy establishes coverage criteria for treating spinal muscular atrophy types 1, 2, 3, and presymptomatic types 1-2, requiring genetic confirmation, specialist prescription, specific dosing regimens, and documented motor function improvement for continuation therapy. No substantive coverage changes are indicated from prior versions; this is a routine annual renewal with the same medical necessity criteria and dosing parameters remaining in effect.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 4 steps
01Billing team should verify that current authorizations and billing procedures for Nusinersen (Spinraza®) claims align with the reissued MA08.086d policy criteria.
02Ensure that prior authorization submissions include: (1) documented genetic testing results confirming 5q-SMA (homozygous SMN1 deletion or equivalent), (2) prescriber credentials confirming neurology or neuromuscular medicine certification, (3) appropriate dosing documentation (lower regimen ≤12 mg every 4 months or higher regimen ≤28 mg every 4 months after loading doses), and (4) for continuation claims, baseline and current motor function assessments using standardized scales (HINE, CHOP-INTEND, or HFMSE).
03No immediate billing system changes are required; this update is informational only for Independence Blue Cross Medicare Advantage members.
04Claims should continue to be processed under existing MA08.086d criteria without workflow modifications.

Codes mentioned

J2326G12.0G12.1

Original notice

MA08.086d, Nusinersen (Spinraza®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.086d, Nusinersen (Spinraza®)LowEffective Jan 1, 2024 · PharmacyMA08.086d, Nusinersen (Spinraza®)LowNo effective date · Pharmacy08.01.36f, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)MediumEffective Mar 23, 2026 · PharmacyMA08.086e, Nusinersen (Spinraza®)MediumEffective Sep 14, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesNJ policy changesNeurologyPediatricsPharmacyPM&R (Physical Medicine & Rehab)Code J2326Code G12.0Code G12.1

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account